Intellia Therapeutics (NTLA) Competitors $27.98 +3.23 (+13.05%) Closing price 04:00 PM EasternExtended Trading$28.24 +0.26 (+0.93%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock NTLA vs. BEAM, CRSP, EDIT, TWST, ELAN, VRNA, RVMD, RGC, ABVX, and MRUSShould you be buying Intellia Therapeutics stock or one of its competitors? The main competitors of Intellia Therapeutics include Beam Therapeutics (BEAM), CRISPR Therapeutics (CRSP), Editas Medicine (EDIT), Twist Bioscience (TWST), Elanco Animal Health (ELAN), Verona Pharma PLC American Depositary Share (VRNA), Revolution Medicines (RVMD), Regencell Bioscience (RGC), Abivax (ABVX), and Merus (MRUS). These companies are all part of the "pharmaceutical products" industry. Intellia Therapeutics vs. Its Competitors Beam Therapeutics CRISPR Therapeutics Editas Medicine Twist Bioscience Elanco Animal Health Verona Pharma PLC American Depositary Share Revolution Medicines Regencell Bioscience Abivax Merus Intellia Therapeutics (NASDAQ:NTLA) and Beam Therapeutics (NASDAQ:BEAM) are both mid-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, analyst recommendations, institutional ownership, dividends, earnings, risk, valuation and profitability. Do insiders & institutionals have more ownership in NTLA or BEAM? 88.8% of Intellia Therapeutics shares are owned by institutional investors. Comparatively, 99.7% of Beam Therapeutics shares are owned by institutional investors. 3.1% of Intellia Therapeutics shares are owned by insiders. Comparatively, 3.5% of Beam Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Is NTLA or BEAM more profitable? Beam Therapeutics has a net margin of -661.31% compared to Intellia Therapeutics' net margin of -908.48%. Beam Therapeutics' return on equity of -43.15% beat Intellia Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Intellia Therapeutics-908.48% -57.48% -45.04% Beam Therapeutics -661.31%-43.15%-31.06% Which has higher earnings and valuation, NTLA or BEAM? Beam Therapeutics has higher revenue and earnings than Intellia Therapeutics. Beam Therapeutics is trading at a lower price-to-earnings ratio than Intellia Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIntellia Therapeutics$57.88M51.89-$519.02M-$4.69-5.97Beam Therapeutics$63.52M48.76-$376.74M-$4.50-6.80 Do analysts prefer NTLA or BEAM? Intellia Therapeutics presently has a consensus price target of $27.95, suggesting a potential downside of 0.11%. Beam Therapeutics has a consensus price target of $45.92, suggesting a potential upside of 49.96%. Given Beam Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Beam Therapeutics is more favorable than Intellia Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Intellia Therapeutics 2 Sell rating(s) 6 Hold rating(s) 13 Buy rating(s) 0 Strong Buy rating(s) 2.52Beam Therapeutics 1 Sell rating(s) 2 Hold rating(s) 10 Buy rating(s) 3 Strong Buy rating(s) 2.94 Which has more volatility and risk, NTLA or BEAM? Intellia Therapeutics has a beta of 2.37, suggesting that its stock price is 137% more volatile than the S&P 500. Comparatively, Beam Therapeutics has a beta of 2.25, suggesting that its stock price is 125% more volatile than the S&P 500. Does the media favor NTLA or BEAM? In the previous week, Intellia Therapeutics and Intellia Therapeutics both had 2 articles in the media. Beam Therapeutics' average media sentiment score of 0.77 beat Intellia Therapeutics' score of 0.52 indicating that Beam Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Intellia Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Beam Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryBeam Therapeutics beats Intellia Therapeutics on 12 of the 16 factors compared between the two stocks. Get Intellia Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NTLA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NTLA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NTLA vs. The Competition Export to ExcelMetricIntellia TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.66B$3.46B$6.15B$10.56BDividend YieldN/A2.27%5.72%4.84%P/E Ratio-5.9723.3929.4727.34Price / Sales51.89482.12586.87132.58Price / CashN/A45.2825.8230.35Price / Book3.2710.6112.526.69Net Income-$519.02M-$52.56M$3.32B$276.46M7 Day Performance17.76%4.94%2.43%0.97%1 Month Performance79.47%16.10%8.78%3.95%1 Year Performance32.73%14.51%62.11%36.40% Intellia Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NTLAIntellia Therapeutics3.8619 of 5 stars$27.98+13.1%$27.95-0.1%+17.4%$2.66B$57.88M-5.97600Gap UpBEAMBeam Therapeutics3.5883 of 5 stars$25.39-3.5%$45.92+80.8%+9.9%$2.57B$60.27M-5.64510Gap UpCRSPCRISPR Therapeutics1.9385 of 5 stars$68.29-6.5%$71.71+5.0%+41.4%$6.21B$35M-12.58460Analyst ForecastInsider TradeAnalyst RevisionEDITEditas Medicine4.0963 of 5 stars$3.56-4.3%$5.10+43.3%+12.2%$320.12M$38.90M-1.25230Gap UpTWSTTwist Bioscience3.8575 of 5 stars$30.14-3.4%$48.50+60.9%-40.0%$1.82B$362.27M-20.79990Gap UpELANElanco Animal Health2.7375 of 5 stars$20.04+1.4%$19.14-4.5%+65.2%$9.96B$4.48B23.309,000Analyst ForecastVRNAVerona Pharma PLC American Depositary Share1.5905 of 5 stars$106.91flat$109.00+2.0%N/A$9.21B$42.28M-107.9930Positive NewsRVMDRevolution Medicines4.4592 of 5 stars$48.75+1.1%$74.64+53.1%+7.3%$9.11BN/A-10.83250Analyst ForecastRGCRegencell Bioscience0.594 of 5 stars$17.99+7.0%N/AN/A$8.90BN/A0.0010ABVXAbivax3.5934 of 5 stars$95.63+2.0%$114.25+19.5%+787.4%$7.44BN/A0.0061Short Interest ↓MRUSMerus1.4205 of 5 stars$94.85+0.5%$93.12-1.8%+80.1%$7.17B$56.23M-17.2537Short Interest ↓ Related Companies and Tools Related Companies Beam Therapeutics Alternatives CRISPR Therapeutics Alternatives Editas Medicine Alternatives Twist Bioscience Alternatives Elanco Animal Health Alternatives Verona Pharma PLC American Depositary Share Alternatives Revolution Medicines Alternatives Regencell Bioscience Alternatives Abivax Alternatives Merus Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NTLA) was last updated on 10/20/2025 by MarketBeat.com Staff From Our PartnersNEW LAW: Congress Approves Setup For Digital Dollar?Trump Ally Says Congress Approved the Setup for a Digital Dollar 2.0 But according to Rep. Marjorie Taylor ...Goldco Precious Metals | SponsoredElon Musk is on the lineElon Musk says November 6 could "affect the future of the world" Get ready for the biggest pivot in corpora...Altimetry | SponsoredWhat Wall Street Won’t Say Out LoudDiscover the 7 key indicators before everyone else doesAmerican Alternative | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredMelt-up warning Porter Stansberry says this bull market is past the “safe zone” and racing toward an event horizon — and in hi...Porter & Company | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredGold to $27,533?This week, U.S. gold reserves hit an unprecedented $1 TRILLION in value... And it's sparking urgent chatter...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Intellia Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Intellia Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
